| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 950 | 2012 |
| Heat-shock proteins as activators of the innate immune system RPA Wallin, A Lundqvist, SH Moré, A von Bonin, R Kiessling, ... Trends in immunology 23 (3), 130-135, 2002 | 785 | 2002 |
| Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against … M Berg, A Lundqvist, P McCoy Jr, L Samsel, Y Fan, A Tawab, R Childs Cytotherapy 11 (3), 341-355, 2009 | 347 | 2009 |
| Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity Y Mao, D Sarhan, A Steven, B Seliger, R Kiessling, A Lundqvist Clinical cancer research 20 (15), 4096-4106, 2014 | 295 | 2014 |
| Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells Y Takahashi, N Harashima, S Kajigaya, H Yokoyama, E Cherkasova, ... The Journal of clinical investigation 118 (3), 1099-1109, 2008 | 230 | 2008 |
| A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer M Pavlenko, AK Roos, A Lundqvist, A Palmborg, AM Miller, V Ozenci, ... British journal of cancer 91 (4), 688-694, 2004 | 219 | 2004 |
| Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms Y Mao, I Poschke, E Wennerberg, Y Pico de Coaña, S Egyhazi Brage, ... Cancer research 73 (13), 3877-3887, 2013 | 188 | 2013 |
| The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment KH Susek, M Karvouni, E Alici, A Lundqvist Frontiers in immunology 9, 402002, 2018 | 185 | 2018 |
| CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo E Wennerberg, V Kremer, R Childs, A Lundqvist Cancer immunology, immunotherapy 64, 225-235, 2015 | 176 | 2015 |
| Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity A Lundqvist, SI Abrams, DS Schrump, G Alvarez, D Suffredini, M Berg, ... Cancer research 66 (14), 7317-7325, 2006 | 176 | 2006 |
| CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment SY Neo, Y Yang, J Record, R Ma, X Chen, Z Chen, NP Tobin, E Blake, ... The Journal of clinical investigation 130 (3), 1185-1198, 2020 | 161 | 2020 |
| IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells Y Mao, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, L Masvidal, ... Blood, The Journal of the American Society of Hematology 128 (11), 1475-1489, 2016 | 157 | 2016 |
| Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker F Salazar-Onfray, M Lopez, A Lundqvist, A Aguirre, A Escobar, A Serrano, ... British journal of cancer 87 (4), 414-422, 2002 | 148 | 2002 |
| Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation R Srinivasan, Y Takahashi, J Philip McCoy, I Espinoza‐Delgado, ... British journal of haematology 133 (3), 305-314, 2006 | 139 | 2006 |
| Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma V Kremer, MA Ligtenberg, R Zendehdel, C Seitz, A Duivenvoorden, ... Journal for immunotherapy of cancer 5, 1-13, 2017 | 135 | 2017 |
| Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma YP de Coana, M Wolodarski, I Poschke, Y Yoshimoto, Y Yang, M Nyström, ... Oncotarget 8 (13), 21539, 2017 | 129 | 2017 |
| Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative … LM Griffith, JP McCoy Jr, CD Bolan, DF Stroncek, AC Pickett, GF Linton, ... British journal of haematology 128 (5), 668-675, 2005 | 126 | 2005 |
| Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors A Lundqvist, J Philip McCoy, L Samsel, R Childs Blood 109 (8), 3603-3606, 2007 | 118 | 2007 |
| Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells A Lundqvist, H Yokoyama, A Smith, M Berg, R Childs Blood, The Journal of the American Society of Hematology 113 (24), 6120-6127, 2009 | 114 | 2009 |
| Natural killer cell immunotherapy for cancer: a new hope S Srivastava, A Lundqvist, RW Childs Cytotherapy 10 (8), 775-783, 2008 | 96 | 2008 |
